Exelixis, Inc. (EXEL) Position Boosted by Keybank National Association OH

Keybank National Association OH increased its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 114.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 44,793 shares of the biotechnology company’s stock after buying an additional 23,893 shares during the period. Keybank National Association OH’s holdings in Exelixis were worth $1,362,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Jennison Associates LLC increased its holdings in Exelixis by 38.1% during the fourth quarter. Jennison Associates LLC now owns 4,228,761 shares of the biotechnology company’s stock worth $128,554,000 after buying an additional 1,167,758 shares during the last quarter. Wells Fargo & Company MN increased its holdings in Exelixis by 36.5% during the third quarter. Wells Fargo & Company MN now owns 3,042,694 shares of the biotechnology company’s stock worth $73,723,000 after buying an additional 814,177 shares during the last quarter. American Century Companies Inc. increased its holdings in Exelixis by 426.4% during the fourth quarter. American Century Companies Inc. now owns 1,469,945 shares of the biotechnology company’s stock worth $44,686,000 after buying an additional 1,190,691 shares during the last quarter. Pictet Asset Management Ltd. increased its holdings in Exelixis by 18.7% during the third quarter. Pictet Asset Management Ltd. now owns 1,317,631 shares of the biotechnology company’s stock worth $31,926,000 after buying an additional 207,868 shares during the last quarter. Finally, Macquarie Group Ltd. increased its holdings in Exelixis by 811.5% during the third quarter. Macquarie Group Ltd. now owns 1,276,453 shares of the biotechnology company’s stock worth $30,928,000 after buying an additional 1,136,409 shares during the last quarter. Institutional investors and hedge funds own 79.48% of the company’s stock.

In other Exelixis news, Director Alan M. Garber sold 15,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $30.30, for a total value of $454,500.00. Following the transaction, the director now directly owns 64,829 shares in the company, valued at $1,964,318.70. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 5.10% of the stock is owned by insiders.

EXEL has been the topic of a number of recent analyst reports. SunTrust Banks restated a “buy” rating and set a $38.00 target price on shares of Exelixis in a report on Thursday, December 21st. William Blair restated an “outperform” rating on shares of Exelixis in a report on Monday, February 12th. BidaskClub downgraded shares of Exelixis from a “buy” rating to a “hold” rating in a report on Friday, January 19th. Cann restated a “hold” rating on shares of Exelixis in a report on Thursday, January 4th. Finally, Oppenheimer restated a “hold” rating on shares of Exelixis in a report on Thursday, January 4th. Six research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $32.13.

Exelixis, Inc. (NASDAQ:EXEL) opened at $28.83 on Wednesday. Exelixis, Inc. has a fifty-two week low of $18.03 and a fifty-two week high of $32.50. The company has a market cap of $8,633.00, a price-to-earnings ratio of 58.84, a price-to-earnings-growth ratio of 0.82 and a beta of 1.84.

COPYRIGHT VIOLATION WARNING: This story was published by BBNS and is the property of of BBNS. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://baseballnewssource.com/markets/exelixis-inc-exel-position-boosted-by-keybank-national-association-oh/1897378.html.

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped


Leave a Reply

 
© 2006-2018 BBNS.